Medigen Vaccine Biologics Corporation - Laporan Laba Rugi (TTM)

Medigen Vaccine Biologics Corporation
TW ˙ TPEX
NT$ 42.55 ↓ -0.30 (-0.70%)
2024-10-25
BAHAGING PRESYO
Laporan Laba Rugi (TTM)

Laporan Laba Rugi Medigen Vaccine Biologics Corporation menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 5 12 14 14 1,258 3,281 3,604 3,616 2,371 365 38 26 242 390 448 623 648 606 662 632
Change (%) 127.41 23.14 -1.54 8,915.92 160.83 9.86 0.32 -34.42 -84.61 -89.48 -32.76 837.14 60.99 15.04 39.09 3.97 -6.56 9.38 -4.58
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 2 4 6 7 379 976 1,090 1,107 734 578 461 444 551 159 173 208 205 209 236 245
Change (%) 143.61 63.60 7.64 5,452.40 157.84 11.69 1.53 -33.70 -21.27 -20.18 -3.77 24.10 -71.05 8.58 20.10 -1.54 2.22 12.75 3.83
% of Revenue 31.40 33.64 44.69 48.86 30.09 29.75 30.24 30.60 30.94 158.24 1,200.47 1,718.04 227.50 40.91 38.62 33.34 31.58 34.54 35.61 38.75
Gross Operating Profit 3 8 8 7 879 2,305 2,514 2,509 1,638 -213 -423 -418 -309 230 275 416 443 396 427 387
Change (%) 119.99 2.63 -8.96 12,225.07 162.12 9.08 -0.20 -34.74 -112.98 98.81 -1.14 -26.15 -174.61 19.51 51.04 6.72 -10.61 7.61 -9.23
% of Revenue 68.60 66.36 55.31 51.14 69.91 70.25 69.76 69.40 69.06 -58.24 -1,100.47 -1,618.04 -127.50 59.09 61.38 66.66 68.42 65.46 64.39 61.25
SG&A 78 92 95 111 134 148 170 177 171 184 178 172 203 243 262 316 333 321 324 309
Change (%) 17.41 3.30 16.49 20.67 11.00 14.42 4.21 -3.22 7.39 -3.29 -3.34 18.44 19.71 7.67 20.67 5.20 -3.66 1.13 -4.80
% of Revenue 1,547.89 799.17 670.38 793.10 10.62 4.52 4.70 4.89 7.21 50.32 462.47 664.82 84.02 62.48 58.48 50.74 51.34 52.93 48.94 48.82
R&D 616 680 833 1,099 1,090 1,193 1,249 1,100 1,259 1,140 1,009 1,058 851 1,201 1,109 841 757 222 174 210
Change (%) 10.32 22.53 31.95 -0.76 9.43 4.72 -11.95 14.44 -9.46 -11.48 4.88 -19.57 41.05 -7.64 -24.12 -10.00 -70.75 -21.34 20.51
% of Revenue 12,173.28 5,905.59 5,876.08 7,874.91 86.68 36.36 34.66 30.42 53.10 312.29 2,627.34 4,098.08 351.71 308.15 247.40 134.96 116.84 36.58 26.30 33.22
OpEx 696 775 934 1,216 1,602 2,317 2,509 2,384 2,164 1,901 1,648 1,674 1,605 1,603 1,544 1,366 1,295 751 734 764
Change (%) 11.43 20.45 30.22 31.75 44.62 8.28 -5.00 -9.22 -12.13 -13.33 1.57 -4.10 -0.11 -3.70 -11.56 -5.19 -41.97 -2.26 3.98
% of Revenue 13,752.57 6,738.40 6,591.16 8,716.86 127.38 70.63 69.61 65.92 91.25 520.85 4,290.28 6,480.94 663.24 411.54 344.50 219.04 199.75 124.05 110.84 120.79
Operating Income -691 -764 -920 -1,202 -344 964 1,095 1,233 207 -1,536 -1,609 -1,648 -1,363 -1,214 -1,096 -742 -647 -146 -72 -131
Change (%) 10.58 20.41 30.71 -71.35 -379.78 13.66 12.52 -83.17 -840.42 4.76 2.39 -17.28 -10.95 -9.72 -32.28 -12.89 -77.47 -50.68 82.91
% of Revenue -13,652.57 -6,638.40 -6,491.16 -8,616.86 -27.38 29.37 30.39 34.08 8.75 -420.85 -4,190.28 -6,380.94 -563.24 -311.54 -244.50 -119.04 -99.75 -24.05 -10.84 -20.79
Interest Expense -17 -16 -13 -11 -8 -6 -6 -11 -19 -27 -34 -37 -38 -38 -38 -34 -26 -19 -12 -9
Change (%) -2.80 -18.25 -20.09 -21.07 -28.90 6.56 75.34 68.74 41.69 27.70 9.10 0.29 0.01 0.36 -11.02 -21.95 -27.86 -37.74 -25.60
% of Revenue -333.83 -142.69 -94.73 -76.88 -0.67 -0.18 -0.18 -0.31 -0.80 -7.37 -89.40 -145.05 -15.52 -9.64 -8.41 -5.38 -4.04 -3.12 -1.78 -1.38
Net Income -678 -674 -700 -706 158 1,410 1,427 1,298 308 -1,475 -1,546 -1,552 -1,295 -1,160 -1,021 -694 -640 -80 -28 -142
Change (%) -0.53 3.77 0.86 -122.33 795.10 1.17 -9.04 -76.24 -578.30 4.87 0.37 -16.57 -10.43 -11.96 -32.03 -7.71 -87.44 -65.09 403.82
% of Revenue -13,396.42 -5,859.74 -4,937.86 -5,057.91 12.53 42.98 39.58 35.89 13.00 -403.95 -4,026.16 -6,009.97 -535.02 -297.68 -227.81 -111.32 -98.81 -13.29 -4.24 -22.39

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista